Biogen and IDEC Pharmaceuticals, two rivals racing to develop drugs for cancer and other diseases, announced plans Monday to merge and create the No. 3 biotechnology company, the latest of a string of ...

Biogen Idec has ended development of its dexpramipexole for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), after the drug candidate failed a pivotal Phase III clinical trial—though the ...

Biogen Idec (NASDAQ: BIIB) and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret. By Walt Bogdanich and Carson Kessler The drug, Kisunla, made by ...

Biotechnology company Biogen Idec Inc. (Nasdaq: BIIB) says it is laying off 13 percent of its work force to cut costs. Biogen, based in Weston, Mass., has about 4,750 employees, with the job cuts ...

During the early days of the biotechnology industry, there were several bellwether companies that analysts and other industry observers kept an eye on to get a sense of the biobusiness world’s health ...

Biogen IDEC Inc's (NASDAQ: BIIB) net income topped Wall Street expectations in the third quarter. To gain insight into why the company reported as it did, investors might review the company's industry ...

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, ...

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

The search is on for a new head. Mullen rose through the ranks at Biogen after coming on as director of facilities and engineering in 1989. He became head of Biogen in 2000, and kept that post when ...

Readers discuss a column by David Brooks. Also: Tears for America; the border reform bill; FAFSA delays; an Alzheimer’s drug; protests in Israel. The pharmaceutical company will give up its ownership ...